RxDoctor Payments Data

Justin Tomal, MD

Gastroenterology · Nampa, IDNPI 1093129751

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 52.4% of the total. That places this record below the midpoint for gastroenterology clinicians in ID, where the typical reported total is $1,538.

$867in general payments, 2019–2025

Across 30 payments — averaging $28.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$454
  • Enterra Medical, Inc.$156
  • Medtronic$137
  • Braintree Laboratories, Inc.$32
  • Intercept Pharmaceuticals, Inc.$21
  • Takeda Pharmaceuticals U.S.A., Inc.$19
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$867100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$867 in reported general payments places this provider in the 35th percentile of 70 gastroenterology providers in Idaho.

See all gastroenterology providers in Idaho

Medicare billing

Part B allowed, 2024
$99,384
Medicare patients
351
Services billed
1,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab16$128,545
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates256$16,553
LinzessLinaclotide21$12,181
Budesonide DrBudesonide20$8,242
Mesalamine13$2,708
Ondansetron OdtOndansetron356$2,460
Budesonide EcBudesonide13$2,112
Pantoprazole Sodium83$1,331
Omeprazole129$1,318
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl58$803
Promethazine Hcl12$796
CholestyramineCholestyramine (With Sugar)12$500
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl27$499
Esomeprazole Magnesium21$476
Famotidine16$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$454$12,18121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 70 gastroenterology providers in Idaho.

Other gastroenterology in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →